Elsevier

Pathology

Volume 45, Issue 2, February 2013, Pages 116-126
Pathology

Tumours associated with BAP1 mutations

https://doi.org/10.1097/PAT.0b013e32835d0efbGet rights and content

Summary

BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds to BRCA1. BAP1 is a tumour suppressor that is believed to mediate its effects through chromatin modulation, transcriptional regulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. Germline mutations of BAP1 confer increased susceptibility for the developmentofseveral tumours, including uveal melanoma, epithelioid atypical Spitz tumours, cutaneous melanoma, and mesothelioma. However, the complete tumour spectrum associated with germline BAP1 mutations is not yet known. Somatic BAP1 mutations are seen in cutaneous melanocytic tumours (epithelioid atypical Spitz tumours and melanoma), uveal melanoma, mesothelioma, clear cell renal cell carcinoma, and other tumours. Here, we review the current state of knowledge about the functional roles of BAP1, and summarise data on tumours associated with BAP1 mutations. Awareness of these tumours will help pathologists and clinicians to identify patients with a high likelihood of harbouring germline or somatic BAP1 mutations. We recommend that pathologists consider testing for BAP1 mutations in epithelioid atypical Spitz tumours and uveal melanomas, or when other BAP1-associated tumours occur in individual patients. Tumour tissues may be screened for BAP1 mutations/loss/inactivation by immunohistochemistry (IHC) (demonstrated by loss of nuclear staining in tumour cells). Confirmatory sequencing may be considered in tumours that exhibit BAP1 loss by IHC and in those with equivocal IHC results. If a BAP1 mutation is confirmed in a tumour, the patient’s treating physician should be informed of the possibility of a BAP1 germline mutation, so they can consider whether genetic counselling and further testing of the patient and investigation of their family is appropriate. Recognition and evaluation of larger numbers of BAP1-associated tumours will also be necessary to facilitate identification of additional distinct clinico-pathological characteristics or other genotype-phenotype correlations that may have prognostic and management implications.

References (88)

  • GillM. et al.

    Lack of BRAF mutations in Spitz nevi

    J Invest Dermatol

    (2004)
  • ScolyerR.A. et al.

    Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma

    Pathology

    (2004)
  • BarnhillR.L. et al.

    Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome

    Hum Pathol

    (1999)
  • BastianB.C. et al.

    Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features

    Am J Pathol

    (2000)
  • JensenD.E. et al.

    BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

    Oncogene

    (1998)
  • AngeloniD.

    Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease

    Brief Funct Genomic Proteomic

    (2007)
  • BottM. et al.

    The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma

    Nat Genet

    (2011)
  • VentiiK.H. et al.

    BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization

    Cancer Res

    (2008)
  • HarbourJ.W. et al.

    Frequent mutation ofBAP1 in metastasizing uveal melanomas

    Science

    (2010)
  • KnudsonA.G.

    Mutation and cancer: statistical study of retinoblastoma

    Proc Natl Acad Sci USA

    (1971)
  • NishikawaH. et al.

    BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity

    Cancer Res

    (2009)
  • MisaghiS. et al.

    Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1

    Mol Cell Biol

    (2009)
  • EletrZ.M. et al.

    An emerging model for BAP1’s role in regulating cell cycle progression

    Cell Biochem Biophys

    (2011)
  • NarayananA. et al.

    The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection

    Proc Natl Acad Sci USA

    (2007)
  • YuH. et al.

    The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression

    Mol Cell Biol

    (2010)
  • GieniR.S. et al.

    Polycomb group proteins in the DNA damage response: a link between radiation resistance and ‘stem-ness’

    Cell Cycle

    (2011)
  • WangH. et al.

    Role of histone H2A ubiquitination in Polycomb silencing

    Nature

    (2004)
  • ScheuermannJ.C. et al.

    Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

    Nature

    (2010)
  • VireE. et al.

    The Polycomb group protein EZH2 directly controls DNA methylation

    Nature

    (2006)
  • O’HaganH.M. et al.

    Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island

    PLoS Genet

    (2008)
  • GreenbergR.A. et al.

    Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes

    Genes Dev

    (2006)
  • JensenD.E.

    Rauscher FJ 3rd. BAP1, a candidate tumor suppressor protein that interacts with BRCA1

    Ann NY Acad Sci

    (1999)
  • MalleryD.L. et al.

    Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains

    EMBO J

    (2002)
  • YoshikawaY. et al.

    Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma

    Cancer Sci

    (2012)
  • COSMIC: catalogue of somatic mutations in cancer. Cited 5 Sept 2012....
  • LadanyiM. et al.

    New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment

    Clin Cancer Res

    (2012)
  • WiesnerT. et al.

    A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression

    Am J Surg Pathol

    (2012)
  • WiesnerT. et al.

    Germline mutations in BAP1 predispose to melanocytic tumors

    Nat Genet

    (2011)
  • Pena-LlopisS. et al.

    BAP1 loss defines a new class of renal cell carcinoma

    Nat Genet

    (2012)
  • Abdel-RahmanM.H. et al.

    Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, menin-gioma, and other cancers

    J Med Genet

    (2011)
  • WadtK. et al.

    A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma

    Pigment Cell Melanoma Res

    (2012)
  • Mihic-ProbstD. et al.

    Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma

    Anticancer Res

    (2004)
  • PalmedoG. et al.

    The T1796A mutation of the BRAF gene is absent in Spitz nevi

    J Cutan Pathol

    (2004)
  • LudgateM.W. et al.

    The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution

    Cancer

    (2009)
  • Cited by (225)

    • The cytologic diagnosis of mesothelioma: are we there yet?

      2023, Journal of the American Society of Cytopathology
    • Molecular pathology and testing in melanocytic tumors

      2023, Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing, Second Edition
    • Malignant and borderline mesothelial tumors of the pleura

      2022, Practical Pulmonary Pathology: A Diagnostic Approach
    View all citing articles on Scopus
    View full text